Navigation Links
ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
Date:5/5/2010

SAN DIEGO, May 5 /PRNewswire/ -- ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents:

On April 13, the Company was granted U.S. Patent 7,695,963, entitled "Methods for Increasing Definitive Endoderm Production".  Methods described in this patent can improve the yield in manufacturing of definitive endoderm and also cells derived from it.

On April 13, the Company was also granted U.S. Patent 7,695,965, entitled "Methods of Producing Pancreatic Hormones".  This patent describes treatment of diabetes with pancreatic progenitor cells derived from human pluripotent stem cells, which develop and mature in vivo to secrete insulin in response to blood glucose levels.  The '965 patent builds on the Company's earlier U.S. Patent 7,534,608, which issued in May 2009.

On April 27, the Company was granted U.S. Patent 7,704,738, entitled "Definitive Endoderm".  The patent has claims covering a method of producing definitive endoderm.  This method has been widely adopted in the field.  It builds on the Company's landmark U.S. Patent 7,510,876, which issued in March 2009.

These new patents add substantially to the Company's U.S. patent estate.  The Company also has a growing number of patents granted outside the United States.  These patents further underscore ViaCyte's leadership position in developing stem cell based therapies for diabetes.  The Company has focused on this development for almost ten years and is increasingly recognized for its science and IP as a result of this focus.

About ViaCyte, Inc.

ViaCyte (formerly Novocell, Inc.) is a preclinical therapeutic company focused on diabetes.  Our therapy is based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells.  These cells are implanted using a durable and retrievable encapsulation device.  Once implanted and matured, these cells secrete insulin in response to blood glucose levels. The Company's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia.  The Company is funded in part through the support of the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York
2. OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its ION free Large Diameter Head Dual Mobility Acetabular Cup System
3. NeoMatrix, Inc., Awarded New Technology Agreement by Novation for HALO(R) Breast Pap Test
4. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
5. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
8. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
9. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
10. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
11. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
(Date:5/4/2017)...  Fortuna Fix Inc. (" Fortuna "), a private, ... eliminate the need for embryonic and fetal stem cells by ... Fortuna announced today the launch of ... , MD, PhD; Father Kevin FitzGerald , S.J., PhD; ... James Giordano , PhD. "We are excited ...
(Date:5/4/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... announced that it is teaming up with Auto Control ... lower diabetes healthcare costs in Canada ... available throughout all provinces and territories in ... additional savings when shopping for Dario supplies in local ...
Breaking Medicine Technology:
(Date:5/19/2017)... ... May 19, 2017 , ... In a continuous effort to ... a luxury online mattress company that specializes in natural and organic latex mattresses, has ... autism organization) for every unique share their recent viral Facebook video receives, ...
(Date:5/19/2017)... , ... May 19, 2017 , ... When Kyle Busch ... his name will already appear on two major research studies that could impact the ... with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Miller Agency, a Jacksonville ... and business owners in the region, is embarking on a cooperative charity event ... families. , Multiple sclerosis (MS) is a demyelinating disease that affects the insulation ...
(Date:5/19/2017)... ... ... As a groundbreaking surgeon on the frontline of prostate cancer treatment, Dr. ... the disease, he says, can make a world of difference. , ... Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and its suggestion to recommend ...
(Date:5/19/2017)... ... May 18, 2017 , ... Eisenhower Fellowships ... eight American presidents of both political parties, will become the 9th Chairman of ... L. Powell, USA (Retired) as Chairman in May, 2018. , Secretary Gates served ...
Breaking Medicine News(10 mins):